Does BMY have more upside than PFE due to BMY having a greater participation than PFE in the economics of the Apixaban program or is it because Apixaban revenue will have more of an impact on BMY's bottom-line compared to PFE?
The latter.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”